Clinical trial
Assessment of Topical Mebo Versus Lidocane in Healing Time of Traumatic Oral Ulcer: Randomized Controlled Trial
Name
RECO6U/15-2023
Description
This study aims to assess topical MEBO application on pain relief and wound healing.
Trial arms
Trial start
2023-07-01
Estimated PCD
2023-08-01
Trial end
2023-08-01
Status
Completed
Treatment
MEBO
MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
Arms:
MEBO group
Lidocaine
Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
Arms:
Control Group
Size
28
Primary endpoint
The degree of pain
10 days after surgery
Eligibility criteria
Inclusion Criteria:
* Age from 20 to 50 years.
* Both sexes.
* Systemically healthy patients.
* Patients with good oral hygiene.
Exclusion Criteria:
* Patients with any uncontrolled local or systemic disease.
* Smokers.
* Pregnancy and lactation.
* Patients allergic to the used agents.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 28, 'type': 'ACTUAL'}}
Updated at
2024-01-03
1 organization
2 products
4 indications
Organization
October 6 UniversityProduct
MEBOIndication
MEBOIndication
LidocaineIndication
HealingIndication
Traumatic Oral UlcerationProduct
Lidocaine